PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 209 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 1.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,000 | -50.0% | 14 | -65.0% | 0.00% | – |
| Q3 2020 | $2,000 | -66.7% | 40 | -76.5% | 0.00% | – |
| Q1 2020 | $6,000 | -25.0% | 170 | 0.0% | 0.00% | – |
| Q4 2019 | $8,000 | +14.3% | 170 | 0.0% | 0.00% | – |
| Q3 2019 | $7,000 | 0.0% | 170 | 0.0% | 0.00% | – |
| Q2 2019 | $7,000 | +16.7% | 170 | 0.0% | 0.00% | – |
| Q1 2019 | $6,000 | -14.3% | 170 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $7,000 | -46.2% | 170 | -37.0% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | +18.2% | 270 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $11,000 | +37.5% | 270 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $8,000 | 0.0% | 270 | +58.8% | 0.00% | 0.0% |
| Q4 2017 | $8,000 | +33.3% | 170 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $6,000 | -25.0% | 170 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $8,000 | 0.0% | 170 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $8,000 | -93.5% | 170 | -94.3% | 0.00% | -97.3% |
| Q3 2015 | $123,000 | -41.4% | 3,000 | 0.0% | 0.04% | -40.3% |
| Q2 2015 | $210,000 | -18.6% | 3,000 | 0.0% | 0.06% | -12.7% |
| Q1 2015 | $258,000 | -11.3% | 3,000 | 0.0% | 0.07% | -33.0% |
| Q3 2014 | $291,000 | – | 3,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |